Is CJC-1295 Legal in Europe?
Is CJC-1295 legal in Europe? It has never been authorised as a medicine anywhere in the world and is explicitly named on the WADA 2026 Prohibited List. An honest, source-cited look at what its RUO status actually means.
CJC-1295 has never received marketing authorisation from the European Medicines Agency or any EU member state — nor from any regulatory authority anywhere in the world. Clinical development was abandoned before approval. In Europe it is supplied legitimately only as a research-use-only reference material, never for human use. It is also explicitly named on the WADA 2026 Prohibited List under S2.2.4 (GHRH analogues), prohibited in sport at all times in both its forms. The question 'is CJC-1295 legal' depends entirely on what you mean: handling it as a characterised research reagent is lawful in much of the EU; using or supplying it for human consumption is not.
CJC-1295 occupies a clear position in the regulatory landscape — and not a comfortable one. Unlike peptides that owe their ambiguous status to obscurity or unresolved classification, CJC-1295 is explicitly named on the WADA 2026 Prohibited List, was never approved as a medicine anywhere in the world, and was removed from the FDA’s compounding-eligible list in 2024. The question “is CJC-1295 legal in Europe” is not wrong, but it is underspecified: legal to handle as a research reagent in a laboratory setting is a different answer from legal to use in or on a human being. Those two answers are not the same, and the distinction matters.
Has CJC-1295 ever been approved as a medicine?
No — not in the EU, not in the USA, not anywhere in the world. CJC-1295 is a synthetic 30-amino-acid analogue of growth-hormone-releasing hormone (GHRH), developed by ConjuChem Technologies in the mid-2000s in two forms: one without a Drug Affinity Complex (DAC), known informally as Modified GRF 1-29, with a plasma half-life of approximately 30 minutes; and one with DAC, which covalently binds to plasma albumin and extends the half-life to roughly six to eight days.45 Both forms were studied in Phase 1 and Phase 2 clinical trials that established their pharmacokinetic profile and confirmed sustained elevation of growth hormone and IGF-1 in healthy adults.45 Development was subsequently abandoned without submission for marketing authorisation. No application was filed with the European Medicines Agency. No application was filed with the FDA. CJC-1295 carries no ATC code and has no approved indication anywhere.
A documented clinical research record is not the same as regulatory approval. The Phase 2 data that exist in the literature characterise the pharmacology of the compound; they do not confer any legal status, prescribability or permission to supply it for human use. The two are distinct, and one does not imply the other.
What does “legal in Europe” actually mean for an unapproved peptide?
EU medicines law is built on Directive 2001/83/EC, the Community code relating to medicinal products for human use.2 That directive defines a medicinal product by two independent tests: by presentation — any substance presented as having properties for treating or preventing disease — and by function — any substance that may be used in or administered to a human being with a view to restoring, correcting or modifying physiological functions through pharmacological, immunological or metabolic action.2 A substance can meet the definition under either test alone. CJC-1295, which acts on pituitary GHRH receptors to stimulate growth hormone secretion, would plausibly meet the by-function test on its pharmacology.
What follows from that? A substance that meets the medicinal-product definition requires marketing authorisation before it can be lawfully placed on the market for human use. CJC-1295 has no such authorisation in any EU member state. The route by which it is lawfully present in European commerce is therefore not as a medicine but as a research-use-only reference material — a characterised reagent supplied strictly for in-vitro and laboratory research, not for administration to human beings.
| Question | Status under the verified facts |
|---|---|
| EMA marketing authorisation | None — never applied for |
| Approved in any EU member state | No |
| Approved anywhere in the world | No |
| ATC code assigned | No |
| Prescribable by an EU physician | No — no lawful route exists |
| Supply as RUO research reagent | Lawful in much of the EU, with RUO framing |
| Supply or use for human consumption | Not permitted under Directive 2001/83/EC |
| Scheduled narcotic / psychotropic (EU/Spain) | No |
| Named on WADA 2026 Prohibited List | Yes — S2.2.4, prohibited at all times, both forms |
| FDA 503A compounding eligibility (USA) | Removed 2024 — no longer eligible |
The WADA position: an explicit prohibition, not a grey zone
CJC-1295 is explicitly named on the World Anti-Doping Agency’s 2026 Prohibited List under section S2.2.4 — Growth-hormone-releasing factors / GHRH analogues — prohibited at all times, classification non-specified.3 This matters because it distinguishes CJC-1295 from peptides whose doping status is uncertain: there is no S0 ambiguity here, no catch-all argument to parse, no “it depends on how the clause is read.” CJC-1295 is on the list by name. Both forms — with DAC and without DAC — are captured by the single entry, because the listing refers to the compound regardless of its pharmacokinetic modification.
Researchers working with athletes, or in institutions subject to WADA-aligned policies, should treat CJC-1295 accordingly. The explicit S2.2.4 designation places it alongside other named GHRH analogues such as sermorelin and tesamorelin in the prohibited-at-all-times category.3 That is a compliance feature that any responsible programme needs to factor in before acquiring or handling the compound. For context on how WADA classifications apply to peptides more broadly, see our overview of peptides on the WADA 2026 Prohibited List.
Zero marketing authorisations exist for CJC-1295 worldwide — in the EU, the USA or any other jurisdiction — despite Phase 2 clinical data published in peer-reviewed literature.
CJC-1295 is explicitly named on the WADA 2026 Prohibited List. This is not an S0 ambiguity — it is a direct, named prohibition under S2.2.4 (GHRH analogues), covering both forms of the compound, at all times.
The 2024 FDA decision: a regulatory signal worth noting
In 2024, the United States Food and Drug Administration removed CJC-1295 from the Category 2 bulk-drug-substances list under Section 503A of the Federal Food, Drug and Cosmetic Act, ending its eligibility for use in compounded human preparations by US pharmacies.6 That is a domestic US decision and carries no direct legal force in the European Union. Nevertheless, it is a meaningful data point: it reflects a deliberate regulatory judgement that CJC-1295 should not be available through an alternative route to approved human use, and it tracks a broader international posture of narrowing the space in which GHRH analogues can be prepared and supplied for human purposes. European researchers should treat this as directional context rather than a binding European ruling.
Is CJC-1295 the same in every EU country?
The EU medicines framework of Directive 2001/83/EC is transposed into national law by each member state, which means that while the underlying architecture is common, the specific classification, handling requirements and enforcement approach for an unapproved compound can vary across the bloc.2 CJC-1295 is not a scheduled narcotic in the EU or in Spain, but the absence of narcotics-schedule status is not the right test. What governs it is medicines law, and the way medicines law is applied — what requires a licence, what constitutes unlawful supply for human use, what triggers enforcement — can differ materially from one member state to the next. Blanket confidence about the legal picture across all 27 member states is not warranted. For a fuller analysis of the regulatory position of RUO reference materials in Europe, see our regulatory position overview.
What does an honest account of the research concede?
The Phase 2 clinical literature on CJC-1295 is real and peer-reviewed. Studies published in the Journal of Clinical Endocrinology & Metabolism and in Endocrinology characterised its pharmacokinetics, documented sustained GH and IGF-1 elevation in healthy adults, and confirmed preserved GH pulsatility during continuous stimulation.45 Earlier preclinical work established its binding profile and identified CJC-1295 as a long-lasting GRF analogue through its albumin-binding mechanism.7 That body of work is why CJC-1295 has a recognised pharmacological profile. It is also the limit of what the research literature can tell you about its legal status: the science characterises what the compound does, and the regulatory system decides what may be done with it. In Europe, what may be done with it is laboratory research on a strictly RUO basis.
Everything Condor Research supplies in this category is a characterised research reference material, sold strictly for research use only.1 It is not an approved or prescribable EU medicine, it is not intended for human or veterinary use, and nothing in this article is a recommendation to use any compound in or on a human being. The distinction between an approved medicine and an RUO reference material is not a formality — it is the entire legal and scientific basis on which legitimate supply rests. This article is for informational purposes only and is not legal advice; responsibility for knowing and complying with applicable local regulation and anti-doping rules rests with the purchaser. The RUO designation is voided the moment the compound is used for human consumption, at which point Directive 2001/83/EC’s requirements apply in full to an unapproved substance. For further context on the EU regulatory framework for RUO research materials, see our regulatory position page.
Research Use Only. This material is supplied strictly as a characterised reference reagent for in-vitro and laboratory research. It is not an approved medicine, is not for human or veterinary use, and nothing above is medical or legal advice. — Condor Research · Scientific desk
- CJC-1295 has never been authorised as a medicine anywhere in the world — not by the EMA, not by any EU member state, and not by the FDA. It carries no ATC code and no approved indication.
- In the EU it is supplied legitimately only as a research-use-only reference material. Offering, labelling or supplying it for human use is not permitted under Directive 2001/83/EC (by presentation or by function).
- CJC-1295 is explicitly named on the WADA 2026 Prohibited List under S2.2.4 (Growth-hormone-releasing factors / GHRH analogues), prohibited in sport at all times, non-specified. Both forms — with and without the Drug Affinity Complex — are captured by the single CJC-1295 entry.
- In 2024 the FDA moved CJC-1295 off its 503A Category 2 bulk-drug-substances list, ending its eligibility for use in compounded human preparations in the United States — a signal of tightening regulatory posture globally.
- CJC-1295 is not a scheduled narcotic or psychotropic in the EU or in Spain, but the absence of narcotics-schedule status is not a licence: medicines law, not narcotics law, governs it.
Is CJC-1295 approved as a medicine anywhere in the EU?
No. CJC-1295 holds no marketing authorisation from the European Medicines Agency and is not approved in any individual EU member state. There is no lawful route by which an EU physician can prescribe it. It is supplied in Europe strictly as a research-use-only reference material, not as a drug.
Has CJC-1295 been approved anywhere in the world?
No. CJC-1295 reached Phase 2 clinical development but was never submitted for, nor granted, marketing authorisation in the EU, the USA or any other jurisdiction. It carries no ATC code and has no approved indication anywhere in the world.
Is CJC-1295 "without DAC" treated differently from CJC-1295 "with DAC"?
Not under WADA rules. The 2026 Prohibited List uses the single entry "CJC-1295" under S2.2.4, capturing both the DAC and non-DAC forms. From a regulatory standpoint both are unapproved synthetic peptides; neither has any approved indication anywhere in the world.
Is CJC-1295 banned in sport?
Yes, explicitly. CJC-1295 is named directly on the WADA 2026 Prohibited List under S2.2.4 (Growth-hormone-releasing factors / GHRH analogues), prohibited at all times, non-specified. This is not an ambiguous S0 case — it is a direct, named prohibition covering both forms of the compound.
Is CJC-1295 a controlled narcotic in the EU or Spain?
No, it is not a scheduled narcotic or psychotropic in the EU or in Spain. However, the absence of narcotics-schedule status is not the relevant test: CJC-1295 is governed by medicines law under Directive 2001/83/EC, and the way national medicines law is applied varies member state to member state. Possession, importation or use for human purposes can carry penalties under medicines regulations even where narcotics law does not apply.
What does the 2024 FDA decision mean in practice?
In 2024 the FDA removed CJC-1295 from the 503A bulk-drug-substances list, ending its eligibility for use in compounded human preparations in the United States. That decision has no direct legal force in the EU, but it is a directional signal: the regulatory trajectory for GHRH analogues is toward restriction, not liberalisation.